




RealRate

PHARMACEUTICAL 2015

Aeolus Pharmaceuticals INC
Rank 158 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Aeolus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeolus Pharmaceuticals INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 155% points. The greatest weakness of Aeolus Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 294% points.

The company's Economic Capital Ratio, given in the ranking table, is 247%, being 7.4% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	3,548
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,995
Liabilities, Non-Current	0
Other Assets	32
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	9,631
Other Revenues	0
Property and Equipment	0
Research and Development	6,966
Selling, General and Administrative Expense	2,745

Output Variable	Value in 1000 USD
Assets	3,580
Liabilities	1,995
Expenses	9,711
Revenues	0
Stockholders Equity	1,585
Net Income	-80
Comprehensive Net Income	-80
BaseVar	12,458
ECR before LimitedLiability	121%
Economic Capital Ratio	247%